196 related articles for article (PubMed ID: 36692074)
1. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
2. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
3. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
4. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
5. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
6. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
7. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
Zhang L; McGraw KL; Sallman DA; List AF
Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
[TBL] [Abstract][Full Text] [Related]
8. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract][Full Text] [Related]
9.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
10. Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.
Asghari H; Talati C
Curr Opin Hematol; 2020 Mar; 27(2):66-75. PubMed ID: 31922971
[TBL] [Abstract][Full Text] [Related]
11. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
Venugopal S; Loghavi S
Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
[TBL] [Abstract][Full Text] [Related]
12. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Daver NG; Maiti A; Kadia TM; Vyas P; Majeti R; Wei AH; Garcia-Manero G; Craddock C; Sallman DA; Kantarjian HM
Cancer Discov; 2022 Nov; 12(11):2516-2529. PubMed ID: 36218325
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin.
Wang Y; Liu Y; Bailey C; Zhang H; He M; Sun D; Zhang P; Parkin B; Baer MR; Zheng P; Malek SN; Liu Y
Oncogene; 2020 Apr; 39(14):3015-3027. PubMed ID: 32060420
[TBL] [Abstract][Full Text] [Related]
14. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
DiGennaro J; Sallman DA
Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
[TBL] [Abstract][Full Text] [Related]
15. Association Analyses of
Wen XM; Xu ZJ; Jin Y; Xia PH; Ma JC; Qian W; Lin J; Qian J
Front Immunol; 2021; 12():717527. PubMed ID: 34745095
[TBL] [Abstract][Full Text] [Related]
16. Development of TP53 mutations over the course of therapy for acute myeloid leukemia.
Alwash Y; Khoury JD; Tashakori M; Kanagal-Shamanna R; Daver N; Ravandi F; Kadia TM; Konopleva M; Dinardo CD; Issa GC; Loghavi S; Takahashi K; Jabbour E; Guerra V; Kornblau S; Kantarjian H; Short NJ
Am J Hematol; 2021 Nov; 96(11):1420-1428. PubMed ID: 34351647
[TBL] [Abstract][Full Text] [Related]
17. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Yan B; Claxton D; Huang S; Qiu Y
Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations in older adults with acute myeloid leukemia.
Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
[TBL] [Abstract][Full Text] [Related]
19. Establishment of tumor protein p53 mutation-based prognostic signatures for acute myeloid leukemia.
Xie J; Chen K; Han H; Dong Q; Wang W
Curr Res Transl Med; 2022 Sep; 70(4):103347. PubMed ID: 35483237
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and characteristics of patients with
Bewersdorf JP; Shallis RM; Gowda L; Wei W; Hager K; Isufi I; Kim TK; Pillai MM; Seropian S; Podoltsev NA; Gore SD; Siddon AJ; Zeidan AM
Leuk Lymphoma; 2020 Sep; 61(9):2180-2190. PubMed ID: 32362171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]